Skip to main content
Premium Trial:

Request an Annual Quote

InforMax Reports Fallen Revenues, Receded R&D, and Narrowed Loss in Q3

NEW YORK, Oct. 30 - InforMax today reported a 35-percent fall-off in revenue atop decreased R&D spending and a narrowed net loss.


For the period ended Sept. 30, InforMax, which two weeks ago said it will be acquired by Invitrogen, had total receipts amounted to $3 million, down from $4.7 million reported during the same quarter one year ago.


R&D spending, like all operating expenses, fell in the third quarter to $2 million compared with $2.5 million year over year, InforMax said.


Consequently, the company said third-quarter net loss narrowed to $5.2 million, or $.20 per share, from $5.4 million, or $.22 per share, during the same period one year ago.


InforMax said it had roughly $46.9 million in cash, cash equivalents, and investments available for sale as of Sept. 30.


Click here for more information.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.